NeuroSense Therapeutics Files 2024 Annual Report
Ticker: NRSNW · Form: 20-F · Filed: Apr 7, 2025 · CIK: 1875091
Sentiment: neutral
Topics: annual-report, 20-f, pharmaceuticals
TL;DR
NeuroSense Therapeutics filed its 2024 20-F, check it for the latest on their pharma biz.
AI Summary
NeuroSense Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel, is focused on pharmaceutical preparations. Its principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya, Israel.
Why It Matters
This filing provides investors with a comprehensive overview of NeuroSense Therapeutics' financial performance and business operations for the past fiscal year, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, NeuroSense Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the annual report.)
- 001-41084 — SEC File Number (The company's SEC filing identification number.)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- 2024 (date) — Fiscal year end
- 11 HaMenofim Street, Building B, Herzliya, Israel (location) — Principal executive offices
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
FAQ
What is the primary business of NeuroSense Therapeutics Ltd. as indicated by its SIC code?
NeuroSense Therapeutics Ltd.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
For which fiscal year is this 20-F filing reporting?
This 20-F filing is for the fiscal year ended December 31, 2024.
Where are NeuroSense Therapeutics Ltd.'s principal executive offices located?
The company's principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya, Israel.
What is the Commission file number for NeuroSense Therapeutics Ltd.?
The Commission file number for NeuroSense Therapeutics Ltd. is 001-41084.
In which jurisdiction was NeuroSense Therapeutics Ltd. incorporated?
NeuroSense Therapeutics Ltd. was incorporated in Israel.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 7, 2025 regarding NeuroSense Therapeutics Ltd. (NRSNW).